Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

Nargiza Parpieva

52 ta ish

Tashkent Pediatric Medical Institute

AkademScholarda batafsil koʻrsatkichlar

  1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

    Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos
    ABI

  2. Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study

    Jamshid Gadoev, Damin Asadov, Mirzagolib Tillashaykhov +14

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20154 iqtibos
    ABI

  3. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Jane Greig +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20164 iqtibos
    ABI

  4. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

    Parvati Nair, T. Hasan, K. K. Zaw +9

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20224 iqtibos
    ABI

  5. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    James M. Trauer, Jay Achar, Nargiza Parpieva +7

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Medicine20163 iqtibos
    ABI

  6. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Nell Gray +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20203 iqtibos
    ABI

  7. Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?

    Sharofiddin Yuldashev, Nargiza Parpieva, Salikhdjan Alimov +6

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20213 iqtibos
    ABI

  8. ‘They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan

    Beverley Stringer, Karen Lowton, Mirzagaleb N. Tillashaikhov +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20162 iqtibos
    ABI

  9. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018

    Khasan Safaev, Nargiza Parpieva, Irina Liverko +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20212 iqtibos
    ABI

  10. Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis

    Aleksandr Trubnikov, Arax Hovhannesyan, Kristina Akopyan +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20212 iqtibos
    ABI

  11. Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan

    Jamshid Gadoev, Damin Asadov, Anthony Harries +9

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20171 iqtibos
    ABI

  12. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

    Johanna Kuhlin, Chris Smith, Atadjan Khaemraev +8

    MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20181 iqtibos
    ABI

  13. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

    S.K. Abidi, Jay Achar, M.M. Assao Neino +34

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos
    ABI

  14. Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia

    A. Engström, Uladzimir Antonenka, Abdylat Kadyrov +10

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20191 iqtibos
    ABI

  15. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

    S. Moe, I. Azamat, Sholpan Allamuratova +14

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyIJTLD OPEN20241 iqtibos
    ABI

  16. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

    Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyClinical Infectious Diseases20251 iqtibos
    ABI

  17. Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?

    Ruzilya Usmanova, Nargiza Parpieva, Hayk Davtyan +6

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20211 iqtibos
    ABI

  18. Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017

    Sherali Massavirov, Kristina Akopyan, Fazlkhan Abdugapparov +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20211 iqtibos
    ABI

  19. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

    Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyERJ Open Research20201 iqtibos
    ABI

  20. Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan

    Shona Horter, Jay Achar, Nell Gray +4

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20201 iqtibos
    ABI

  21. Diagnostic Procedures, Diagnoses, and Treatment Outcomes of Patients with Presumptive Tuberculosis Pleural Effusion in Uzbekistan

    Fazlkhan Abdugapparov, Ruzanna Grigoryan, Nargiza Parpieva +7

    MaqolaOchiq kirishPleural and Pulmonary DiseasesInternational Journal of Environmental Research and Public Health20211 iqtibos
    ABI

  22. Short-term clinical and microbiological outcomes of biomayrin, a polygalacturonic acid-associated fixed-dose antituberculosis formulation: A randomized pilot study

    Nargiza Parpieva, V G Belotserkovets, Shavkat A. Shomurotov +2

    MaqolaOchiq kirish20260 iqtibos
    ABI

  23. [Features of disruption of certain components of carbohydrate metabolism in a combination of pulmonary tuberculosis and diabetes mellitus in people with haptoglobin phenotypes].

    Nargiza Parpieva, K S Kazakov

    MaqolaErythrocyte Function and PathophysiologyPubMed20010 iqtibos
    ABI

  24. Mutations in the genes of drug-resistant mycobacterium tuberculosis in Uzbekistan

    Nargiza Parpieva, Vera Beloserkoves, Khasan Safaev +1

    MaqolaTuberculosis Research and EpidemiologyEuropean Respiratory Journal20140 iqtibos
    ABI

  25. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

    Jay Achar, Catherine Berry, Krzysztof Herboczek +7

    BoshqaOchiq kirishTuberculosis Research and EpidemiologyEmerging infectious diseases20150 iqtibos
    ABI